INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20901, 4532, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20902, 5871, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20903, 7518, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20904, 10359, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20905, 10360, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20906, 10361, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20907, 10363, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20908, 10364, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20909, 11670, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20910, 14114, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20911, 15916, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20912, 16428, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20913, 21273, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20914, 25476, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20915, 25477, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20916, 25524, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20917, 25525, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20918, 25529, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20919, 25539, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20920, 25540, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20921, 25541, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20922, 25542, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20923, 25543, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20924, 25544, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20925, 25545, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20926, 25558, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20927, 25559, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20928, 25560, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20929, 25561, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20930, 25562, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20931, 25564, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20932, 25565, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20933, 25566, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20934, 25567, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20935, 25568, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20936, 26461, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20937, 26856, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20938, 26859, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20939, 26861, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20940, 26862, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20941, 27396, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20942, 27397, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20943, 28509, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20944, 31154, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20945, 33456, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20946, 33457, 'Quetiapine', 'Cataract', 'Prolonged use of quetiapine was associated with the development of cataracts in dogs.  Lens changes have also been observed in humans during chronic treatment with quetiapine, but a causal relationship has not been established.  Long-term therapy with quetiapine should be administered cautiously in patients with a history of cataracts.  Examination of the lens by slit lamp exam or other appropriately sensitive methods is recommended at initiation of treatment or shortly thereafter and at 6-month intervals during chronic treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20947, 1191, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20948, 1630, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20949, 4532, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20950, 5871, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20951, 7518, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20952, 10359, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20953, 10360, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20954, 10361, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20955, 10363, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20956, 10364, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20957, 11670, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20958, 14114, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20959, 15916, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20960, 16428, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20961, 21273, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20962, 25476, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20963, 25477, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20964, 25524, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20965, 25525, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20966, 25529, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20967, 25539, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20968, 25540, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20969, 25541, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20970, 25542, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20971, 25543, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20972, 25544, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20973, 25545, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20974, 25558, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20975, 25559, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20976, 25560, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20977, 25561, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20978, 25562, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20979, 25564, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20980, 25565, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20981, 25566, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20982, 25567, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20983, 25568, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20984, 26461, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20985, 26856, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20986, 26859, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20987, 26861, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20988, 26862, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20989, 27396, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20990, 27397, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20991, 28509, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20992, 31154, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20993, 33456, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20994, 33457, 'Quetiapine', 'Hyperlipidemias', 'According to the manufacturer, patients treated with quetiapine in 3- to 6-week placebo-controlled trials had increases in cholesterol and triglyceride of 11% and 17%, respectively, compared to slight decreases in the placebo group.  Patients with preexisting hyperlipidemia may require closer monitoring during quetiapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20995, 1191, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20996, 1630, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20997, 4532, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20998, 5871, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (20999, 7518, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21000, 10359, 'Quetiapine', 'Hypothyroidism', 'During clinical trials, the use of quetiapine was associated with a dose-related decrease in total and free thyroxine (T4) levels that reached approximately 20% at the higher end of the therapeutic dose range and peaked within the first 2 to 4 weeks of treatment.  Generally, the changes were of no clinical significance and were reversible following discontinuation of quetiapine regardless of the duration of treatment.  TBG levels were not altered in any patient, while TSH increased in 0.4% (10/2386) of patients, some of whom required thyroid replacement therapy.  Therapy with quetiapine should be administered cautiously in patients with thyroid disease.  Closer monitoring of thyroid function may be appropriate following initiation or cessation of quetiapine.', '2', '', 'DDInter', 0);
